Alkermes plc (ALKS) Reaches $58.50 After 4.00% Down Move; Starrett L S Co (SCX) Sentiment Is 1.22

February 22, 2018 - By Nellie Frank

The L.S. Starrett Company manufactures and sells industrial, professional, and consumer measuring and cutting tools and related products primarily in North America, Brazil, China, and the United Kingdom. The company has market cap of $52.95 million. The companyÂ’s products include precision tools, electronic gages, gage blocks, optical vision and laser measuring equipment, custom engineered granite solutions, squares, band saw blades, hole saws, hacksaw blades, jig saw blades, and reciprocating saw blades, as well as M1 lubricant and precision ground flat stock products. It currently has negative earnings. It also provides measuring tools, such as micrometers, vernier calipers, height gages, depth gages, electronic gages, dial indicators, steel rules, and combination squares, as well as custom, non-contact, and in-process gaging products comprising optical, vision, and laser measurement systems; and force measurement and material test equipment.

The stock of Alkermes plc (NASDAQ:ALKS) is a huge mover today! The stock decreased 7.43% or $4.695 during the last trading session, reaching $58.495. About 671,859 shares traded. Alkermes plc (NASDAQ:ALKS) has risen 47.50% since February 22, 2017 and is uptrending. It has outperformed by 30.80% the S&P500.The move comes after 9 months negative chart setup for the $9.13B company. It was reported on Feb, 22 by Barchart.com. We have $56.16 PT which if reached, will make NASDAQ:ALKS worth $365.36 million less.




The stock increased 0.06% or $0.005 during the last trading session, reaching $8.455. About 1,660 shares traded. The L.S. Starrett Company (SCX) has declined 8.13% since February 22, 2017 and is downtrending. It has underperformed by 24.83% the S&P500.

Teton Advisors Inc. holds 0.29% of its portfolio in The L.S. Starrett Company for 348,498 shares. Morgan Dempsey Capital Management Llc owns 15,003 shares or 0.05% of their US portfolio. Moreover, Qci Asset Management Inc Ny has 0.05% invested in the company for 54,864 shares. The New York-based Gamco Investors Inc. Et Al has invested 0.02% in the stock. Gsa Capital Partners Llp, a United Kingdom-based fund reported 31,410 shares.

Investors sentiment decreased to 1.04 in 2017 Q3. Its down 0.08, from 1.12 in 2017Q2. It worsened, as 32 investors sold Alkermes plc shares while 64 reduced holdings. 32 funds opened positions while 68 raised stakes. 144.69 million shares or 1.07% more from 143.16 million shares in 2017Q2 were reported. Apg Asset Mngmt Nv invested in 81,038 shares. Blackrock has 0.03% invested in Alkermes plc (NASDAQ:ALKS). Moreover, Trillium Asset Management Limited Liability Co has 0.14% invested in Alkermes plc (NASDAQ:ALKS) for 48,519 shares. X Mgmt Lc invested 0% in Alkermes plc (NASDAQ:ALKS). Marsico Capital Ltd Company has 0.08% invested in Alkermes plc (NASDAQ:ALKS) for 39,854 shares. Wellington Mngmt Gru Llp holds 0.24% of its portfolio in Alkermes plc (NASDAQ:ALKS) for 20.21M shares. Tiaa Cref Investment Mgmt Ltd Co stated it has 311,264 shares or 0.01% of all its holdings. 150,251 were reported by Baker Bros Limited Partnership. Aviance Capital Limited Company accumulated 4,000 shares or 0.07% of the stock. Voya Inv Management Ltd Liability owns 66,007 shares for 0.01% of their portfolio. Frontier Company Ltd invested 0.29% in Alkermes plc (NASDAQ:ALKS). Roanoke Asset Mngmt Ny has invested 1.64% of its portfolio in Alkermes plc (NASDAQ:ALKS). Credit Suisse Ag invested 0.02% in Alkermes plc (NASDAQ:ALKS). Fiera Corp, Quebec – Canada-based fund reported 636,803 shares. Panagora Asset Mgmt Incorporated holds 10,965 shares.

Analysts await Alkermes plc (NASDAQ:ALKS) to report earnings on April, 26. They expect $-0.22 earnings per share, up 29.03% or $0.09 from last year’s $-0.31 per share. After $0.20 actual earnings per share reported by Alkermes plc for the previous quarter, Wall Street now forecasts -210.00% negative EPS growth.

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products that are designed to address unmet medical needs of patients in various therapeutic areas worldwide. The company has market cap of $9.13 billion. The companyÂ’s marketed products include ARISTADA for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; AMPYRA (dalfampridine)/FAMPYRA (fampridine) to enhance walking in adults with multiple sclerosis who have walking disability; and BYDUREON (exenatide extended-release for injectable suspension) for the treatment of type 2 diabetes. It currently has negative earnings. It is also developing ALKS 5461 that is in Phase III clinical trials for the treatment of depressive disorder; ALKS 3831, which is in Phase III clinical trials to treat schizophrenia; ALKS 8700, a monomethyl fumarate molecule, which is in Phase III clinical trials to treat multiple sclerosis; ALKS 6428, which is in Phase III clinical trials to help physicians transition patients from physical dependence on opioids; and Aripiprazole lauroxil, an injectable atypical antipsychotic, which has completed a Phase I clinical trials for the treatment of schizophrenia, as well as ALKS 4230, a cell activator that is in Phase I clinical trials for cancer immunotherapy.

Among 13 analysts covering Alkermes (NASDAQ:ALKS), 8 have Buy rating, 0 Sell and 5 Hold. Therefore 62% are positive. Alkermes had 35 analyst reports since September 1, 2015 according to SRatingsIntel. On Thursday, July 27 the stock rating was maintained by Cantor Fitzgerald with “Hold”. Mizuho maintained the shares of ALKS in report on Friday, October 20 with “Buy” rating. The firm has “Overweight” rating by JP Morgan given on Friday, October 21. The firm has “Overweight” rating by Barclays Capital given on Friday, July 29. Cowen & Co maintained the stock with “Buy” rating in Friday, October 27 report. The rating was maintained by Leerink Swann with “Hold” on Thursday, July 27. The firm has “Outperform” rating given on Friday, October 27 by Credit Suisse. The rating was downgraded by Barclays Capital to “Equal-Weight” on Monday, October 16. On Thursday, June 29 the stock rating was maintained by J.P. Morgan with “Buy”. Leerink Swann downgraded the shares of ALKS in report on Tuesday, June 13 to “Market Perform” rating.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: